Education
About Us
Working with TipRanks
Follow Us
Skye Bioscience, Inc. (SKYE)
:SKYE
SKYE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.14 - $7.47
Previous CloseN/A
Volume18.00K
Average Volume (3M)555.88K
Market Cap
$108.77M
Enterprise Value$117.56M
Total Cash (Recent Filing)$59.22M
Total Debt (Recent Filing)$412.11K
Price to Earnings (P/E)―
Beta2.24
Next Earnings
Nov 06, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding30,988,420
10 Day Avg. Volume298,881
30 Day Avg. Volume555,880
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-3.85
Enterprise Value/Market Cap1.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.73
Forecast
1Y Price Target
$17.33Price Target Upside393.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical TrialsNimacimab demonstrated slower weight rebound kinetics relative to tirzepatide following the cessation of therapy.
PartnershipsThe collaboration with Arecor Therapeutics could enable testing higher doses of nimacimab, potentially allowing for once-monthly dosing during future clinical development.
Safety And EfficacyA fourth Data Safety Monitoring Committee convened and did not raise any safety concerns, and thus the Phase IIa CBeyond study will continue.
Bears Say
Clinical Data ReleaseThe interim data from the Phase IIa CBeyond trial will no longer be released as initially planned.
Financial PerformanceSkye reported a net loss of $9.7 million, which was in line with estimates but still represents a financial loss.
Skye Bioscience News
SKYE FAQ
What was Skye Bioscience, Inc.’s price range in the past 12 months?
Skye Bioscience, Inc. lowest stock price was $1.14 and its highest was $7.47 in the past 12 months.
What is Skye Bioscience, Inc.’s market cap?
Skye Bioscience, Inc.’s market cap is $108.77M.
When is Skye Bioscience, Inc.’s upcoming earnings report date?
Skye Bioscience, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 85 days.
How were Skye Bioscience, Inc.’s earnings last quarter?
Skye Bioscience, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.32 by -$0.12.
Is Skye Bioscience, Inc. overvalued?
According to Wall Street analysts Skye Bioscience, Inc.’s price is currently Undervalued.
Does Skye Bioscience, Inc. pay dividends?
Skye Bioscience, Inc. does not currently pay dividends.
What is Skye Bioscience, Inc.’s EPS estimate?
Skye Bioscience, Inc.’s EPS estimate is -0.31.
How many shares outstanding does Skye Bioscience, Inc. have?
Skye Bioscience, Inc. has 30,988,420 shares outstanding.
What happened to Skye Bioscience, Inc.’s price movement after its last earnings report?
Skye Bioscience, Inc. reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.32. Following the earnings report the stock price went down -0.845%.
Which hedge fund is a major shareholder of Skye Bioscience, Inc.?
Currently, no hedge funds are holding shares in SKYE
Skye Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.33 (393.73% Upside)
$17.33 (393.73% Upside)
Blogger Sentiment
Bullish
SKYE Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 171.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.34%
12-Months-Change
Fundamentals
Return on Equity
-72.75%
Trailing 12-Months
Asset Growth
-40.22%
Trailing 12-Months
Company Description
Skye Bioscience, Inc.
Skye Bioscience (SKYE) is a biotechnology company focused on the discovery, development, and commercialization of innovative pharmaceutical products intended to address unmet needs in various therapeutic areas. The company primarily operates in the biopharmaceutical sector, with a core emphasis on ocular diseases. Skye Bioscience is committed to advancing its pipeline of cannabinoid-derived compounds, leveraging its proprietary technologies to develop novel treatments that have the potential to improve patient outcomes.
SKYE Company Deck
SKYE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook for Skye Bioscience, with significant progress in the clinical development of nimacimab, strong financial positioning, and strategic team expansion. However, increased R&D expenses and a higher net loss were noted as challenges. Overall, the positive developments and strategic plans outweigh the financial concerns and operational challenges.View all SKYE earnings summariesSKYE Stock 12 Month Forecast
Average Price Target
$17.33
▲(393.73% Upside)
Technical Analysis
Alterity Therapeutics
―
Actinium Pharmaceuticals
―
Mersana Therapeutics
―
Celularity
―
OnKure Therapeutics
―
Ownership Overview
66.72% Insiders
4.91% Mutual Funds
0.95% Other Institutional Investors
23.69% Public Companies and Individual Investors